Morgan Stanley Call 190 ABBV 21.0.../ DE000MB9SUZ0 /
13/05/2024 20:16:53 | Chg.0.000 | Bid22:00:33 | Ask22:00:33 | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
0.400EUR | 0.00% | - Bid Size: - |
- Ask Size: - |
AbbVie Inc | 190.00 USD | 21/06/2024 | Call |
GlobeNewswire
00:14
In NCLA Amicus Win, and FTC Amicus Loss, Second Circuit Upholds Decision Dismissing Antitrust Suit
GlobeNewswire
09/05
Nxera Pharma’s partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of...
GlobeNewswire
08/05
CytomX Therapeutics Announces Positive Initial Phase 1a Dose Escalation Data for Monotherapy CX-904 ...
GlobeNewswire
08/05
CytomX Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
08/05
Alector Reports First Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
08/05
Coherus Announces Clinical Collaboration with the Cancer Research Institute for a Novel Combination ...
GlobeNewswire
08/05
Jnana Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference
GlobeNewswire
07/05
CytomX Therapeutics Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination wi...
GlobeNewswire
07/05
Caribou Biosciences Reports First Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
06/05
Pacific Software Inc. Announces a Landmark Asset Acquisition from Dreamaderm Inc.
GlobeNewswire
02/05
Aprea Therapeutics Announces Appointment of Nadeem Q. Mirza, M.D., M.P.H. as Chief Medical Officer a...
GlobeNewswire
01/05
CytomX Therapeutics to Report First Quarter 2024 Results and Provide an Initial CX-904 Phase 1a Clin...
GlobeNewswire
30/04
CEREVEL SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Cerevel Therapeutics Holdings,...
GlobeNewswire
30/04
U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentratio...
GlobeNewswire
25/04
Morphic Announces Corporate Highlights and Financial Results for the First Quarter 2024
GlobeNewswire
25/04
Nucleome Therapeutics appoints Dr John Davis as Non-Executive Director of the Board and establishes ...